Results 11 to 20 of about 44,177 (299)
Dermatology Online Journal, 2013 We present a case of chronic graft-versus-host disease in a 61-year-old woman with a history of B-cell chronic lymphocytic leukemia that was treated with an allogeneic bone marrow transplant from an unrelated donor.
Latkowski, Jo-Ann +3 more
core +6 more sources
Frontiers in Immunology, 2020 Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease?
Elizabeth Krieger, Amir Ahmed Toor
doaj +3 more sources
Haematologica, 2016 Improvement of graft-versus-host disease prophylaxis remains an important goal in allogeneic hematopoietic stem cell transplantation. Based on reports of possibly preferential properties of sirolimus, we compared the standard regimen of cyclosporine and ...
Johan Törlén +8 more
doaj +3 more sources
Body Composition Assessment Provides Prognostic Information in Patients With Cancer Affected by Chronic Graft vs. Host Disease [PDF]
Journal of Cachexia, Sarcopenia and MuscleBackground Additional tools are needed to assess mortality risk among patients with cancer. Patients with chronic graft vs. host disease (cGVHD) after allogeneic haematopoietic cell transplantation (HCT) represent a high‐risk cancer population with ...
Asmita Mishra +8 more
doaj +2 more sources
Inflammatory Cytokine Networks in Gastrointestinal Tract Graft vs. Host Disease [PDF]
Frontiers in Immunology, 2019 Graft vs. host disease (GVHD) is the major non-relapse complication associated with allogeneic hematopoietic stem cell transplantation (HSCT). Damage to the gastrointestinal (GI) tract from acute GVHD is a particularly serious event that can result in ...
Clint Piper +2 more
doaj +2 more sources
Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance [PDF]
Frontiers in Immunology, 2019 Graft-vs.-host disease (GVHD) remains a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Hongshuang Yu +5 more
doaj +2 more sources
Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease [PDF]
Frontiers in Immunology, 2019 Acute graft-vs.-host disease (GVHD) limits the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a main therapy to treat various hematological disorders.
Govindarajan Thangavelu, Bruce R. Blazar
doaj +2 more sources
AAV-mediated expression of HLA-G for the prevention of experimental ocular graft vs. host disease [PDF]
Molecular Therapy: Methods & Clinical Development, 2023 Ocular graft versus host disease (OGvHD) develops after allogeneic hematopoietic stem cell transplantation (HSCT) and manifests as ocular surface inflammatory disease.
Jacob P. Nilles +8 more
doaj +2 more sources
Haematologica, 2015 Effective pharmacological strategies employed in allogeneic hematopoietic cell transplantation should prevent serious chronic graft-versus-host disease and facilitate donor-recipient immune tolerance.
Joseph Pidala +15 more
doaj +3 more sources
Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience [PDF]
Frontiers in Bioengineering and Biotechnology, 2018 The most effective treatment of steroid refractory acute graft vs. host disease (aGvHD) is not yet established and mesenchymal stem cells (MSC) appear to be a promising therapy for the condition. We report single center case series of three patients, who
Maja Česen Mazič +4 more
doaj +2 more sources